The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
JenkinsJ.M., WilliamsD., DengY.Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor antagonist. Blood.2007; 109(11): 4739–4741.
2.
BusselJ.B., ChengG., SalehM.N.Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med.2007; 357(22): 2237–2247.
3.
ChengG., SalehM., BusselJ.Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: results of a phase III, double-blind, placebo-controlled study (RAISE). ASH Annual Meeting Abstracts. Blood.2008; 112: abstract 400.
4.
BusselJ., ChengG., SalehM.Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura. ASH Annual Meeting Abstracts. Blood.2008; 112: abstract 3432.
5.
Promacta [package insert].Research Triangle Park, NC: GlaxoSmithKline; 2008.
6.
McHutchisonJ.G., DusheikoG., ShiffmanM.L.Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med.2007; 357(22): 2227–2236.
7.
BusselJ., SalehM., ProvanD.Eltrombopag, a novel, oral platelet growth factor, increases platelet counts in thrombocytopenic patients and healthy subjects. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol.2006; 24(18S): abstract 8602.
8.
FogartyP., BusselJ., ChengG.Oral eltrombopag treatment reduces the need for concomitant medications in patients with chronic idiopathic thrombocytopenic purpura. ASH Annual Meeting Abstracts. Blood.2008; 112: abstract 3424.
9.
WangB., NicholJ.L., SullivanJ.T.Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther.2004; 76(6): 628–638.
10.
NewlandA., CaulierM.T., Kappers-KlunneM.An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol.2006; 135(4): 547–553.
11.
BusselJ.B., KuterD.J., GeorgeJ.N.AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med.2006; 355(16): 1672–1681.
12.
KumagaiY., FujitaT., OzakiM.Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol.2007; 47(12): 1489–1497.
13.
KuterD.J., BusselJ.B., LyonsR.M.Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet.2008; 371(9610): 395–403.
14.
BusselJ.B., KuterD.J., PullarkatV., LyonsR.M., GuoM., NicholJ.L.Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP [published online ahead of print November 2008]. Blood.
15.
TiuR.V., SekeresM.A.The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes. Expert Opin Biol Ther.2008; 8(7): 1021–1030.
16.
RiceL.Drug evaluation: AMG-531 for the treatment of thrombocytopenias. Curr Opin Investig Drugs.2006; 7(9): 834–841.
17.
KuterD.J.Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia [published online ahead of print October 2008]. Annu Rev Public Health.
